BB Biotech AG Releases Interim Report with Positive Net Profit

BB Biotech AG has published its interim report for the first nine months of 2024 as of September 30, 2024. According to the consolidated accounts, the company reported a net profit of CHF 16 million, a significant turnaround from the loss of CHF 316 million recorded in the same period in 2023. However, the third quarter revealed a loss of CHF 157 million, compared to a loss of CHF 48 million in the same quarter of the previous year.

The interim report, which reflects the performance of the stocks held in BB Biotech AG's portfolio, is now accessible online. Headquartered in Schaffhausen, Switzerland, BB Biotech is noted for its investments in innovative drug developers, primarily based in the US and Western Europe. It remains one of the largest investors in this sector globally.